세계 약물 용출 스텐트 시장(2023-2030년)

Global Drug-eluting Stent Market Size, Share & Trends Analysis Report by material (Stainless Steel, Cobalt-Chromium Alloy, and Others), By Type, (Permanent and Biodegradable), By Application (Coronary Artery Stenting and Peripheral Artery Stenting), and by End-User (Hospitals and Cardiac Catheterization Laboratories), Forecast Period (2024-2031)

The global drug-eluting stent market is anticipated to grow at a CAGR of 7.6% during the forecast period (2023-2030). Some of the major factors attributed to the market growth include the rising geriatric population, increasing prevalence of cardiovascular diseases (peripheral and coronary artery diseases), favorable government initiatives and policies, and the introduction of new and enhanced technological products. The American Heart Association (AHA) published an article called "Health Disparities in Peripheral Artery Disease": A Scientific Statement from the AHA, according to which peripheral artery disease (PAD) affects 200 million individuals globally. In the US, certain demographic groups experience a disproportionately higher prevalence and clinical effect of PAD. The social and clinical effect of PAD includes higher rates of individual disability, depression, minor and major limb amputation along with cardiovascular and cerebrovascular events.

Segmental Outlook

The global drug-eluting stent market is segmented by material, product, type, application, and end-users. Based on the material, the market is sub-segmented into stainless steel, cobalt-chromium alloy, and others. Others include platinum-chromium alloy. Based on the type, the market is sub-segmented into permanent, and biodegradable. Based on the application, the market is divided into coronary artery stenting and peripheral artery stenting. Further, based on end-users, the market is sub-segmented into hospitals and cardiac catheterization laboratories. Among the end-users, the hospitals sub-segment is anticipated to hold the largest market share during the forecast period, owing to the lower costs, higher efficiency, and availability.

The Coronary Artery Stenting Sub-Segment is Anticipated to Hold a Considerable Share of the Global Drug-Eluting Stent Market

Among the applications, the coronary artery stenting sub-segment is expected to grow over the forecast period. Segmental growth is attributed to the increasing incidence of coronary artery diseases (CAD), technological advancements, and cohesive government policies. Among all CVDs, CAD has the highest prevalence. The British Heart Foundation (BHF) data published in January 2023 reported that in 2021, the most common cardiovascular conditions are coronary (ischemic) heart disease (global prevalence estimated at 200 million in 2019), peripheral arterial (vascular) disease (110 million), stroke (100 million) and atrial fibrillation (60 million). Additionally, the report revealed that the prevalence of heart and circulatory diseases in North America was 48 million, in Europe it was 100 million, in Africa and the Middle East it was 98 million, in Latin America it was 48 million, and in Asia and Australia it was 340 million.

Regional Outlook

The global drug-eluting stent market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Europe is anticipated to grow over the forecast period, owing to the increasing geriatric population, increasing prevalence of coronary artery diseases the rising healthcare expenditure, driving the drug-eluting stent market in Europe.

The North American region is Expected to Grow at a Significant CAGR in the Global Drug-eluting Stent Market

North America is expected to hold a prominent share in the Drug-eluting Stent market during the forecast period. With the rising elderly population, there is an increased inclination to arterial diseases, requiring more effective treatment solutions such as drug-eluting stents. The prevalence of atherosclerosis, marked by the increase of plaque in arteries, has also surged owing to sedentary lifestyles and poor dietary choices. According to research reports published by the National Institutes of Health (NIH), in March 2020, the prevalence of atherosclerotic cardiovascular disease (ASCVD) among adults in the US is 18.3 million (8.0%). This condition significantly contributes to various cardiovascular diseases, including heart attacks and strokes. In response to this mounting health concern, medical professionals are increasingly turning to drug-eluting stents as a preferred treatment for atherosclerosis. According to the American Heart Association, in 2020 in the US, coronary heart disease (CHD) was the leading cause (41.2%) of deaths attributable to CVD in the US, followed by stroke (17.3%), other CVD (16.8%), high blood pressure (12.9%), and heart failure (9.2%). The prevalence of atherosclerotic cardiovascular disease (ASCVD) amongst adults in the US is 18.3 million (8.0%). 690,524 adults had an acute coronary syndrome event last year, and over 6 million are at very high risk.

Market Players Outlook

The major companies serving the drug-eluting stent market include Abbott Laboratories, Boston Scientific Corp., Biotronik SE & Co. KG, Medtronic Plc, Terumo Corp., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in May 2023, CoSo Health signed a US distribution agreement with Medinol for EluNIR™, a new generation, thin-strut drug-eluting stent (DES). Medinol is a pioneer in the development of implantable medical devices.

The Report Covers:

• Market value data analysis of 2023 and forecast to 2031.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global drug-eluting stent market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. Abbott Laboratories
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Boston Scientific Corp.
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. Biotronik SE & Co. KG
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Medtronic Plc
  • 3.5.1. Overview
  • 3.5.2. Financial Analysis
  • 3.5.3. SWOT Analysis
  • 3.5.4. Recent Developments
• 3.6. Terumo Corp.
  • 3.6.1. Overview
  • 3.6.2. Financial Analysis
  • 3.6.3. SWOT Analysis
  • 3.6.4. Recent Developments
• 3.7. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Drug-Eluting Stent Market by Material
  • 4.1.1. Stainless Steel
  • 4.1.2. Cobalt-Chromium Alloy
  • 4.1.3. Others (Platinum-Chromium Alloy)
• 4.2. Global Drug-Eluting Stent Market by Type
  • 4.2.1. Permanent
  • 4.2.2. Biodegradable
• 4.3. Global Drug-Eluting Stent Market by Application
  • 4.3.1. Coronary Artery Stenting
  • 4.3.2. Peripheral Artery Stenting
• 4.4. Global Drug-eluting Stent Market by End-User
  • 4.4.1. Hospitals
  • 4.4.2. Cardiac Catheterization Laboratories

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World

6. Company Profiles

• 6.1. Alvimedica SA
• 6.2. B. Braun SE
• 6.3. Biosensors International Group, Ltd.
• 6.4. Cardionovum GmbH
• 6.5. Cook Group Inc.
• 6.6. Elixir Medical Corp.
• 6.7. Hexacath
• 6.8. InspireMD Inc.
• 6.9. JW Medical Systems LTD.
• 6.10. Lepu Medical Technology (Beijing) Co., Ltd.
• 6.11. MicroPort Scientific Corp.,
• 6.12. OrbusNeich Medical Co. Group Holdings Ltd.
• 6.13. Sino Medical Sciences Technology Inc.
• 6.14. Translumina GmbH
• 6.15. Vascular Concepts Ltd.